Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00318890 · ClinicalTrials.gov registry record · Phase 1
Cisplatin and Docetaxel Plus Docetaxel and Radiotherapy With Amifostine for Squamous Cell Carcinoma of the Head and Neck
A Phase 1 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT00318890 is a Phase 1 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 48 participants.
The verdict
NCT00318890, a Phase 1 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
This trial seeks to accomplish both local and regional control of head and neck cancer and reduce systemic metastatic disease. To do this, patients will received chemotherapy followed by chemotherapy and radiation (given together) with an escalating dose of docetaxel.
Interventions
- DRUG Docetaxel
- DRUG Cisplatin
- PROCEDURE Radiotherapy
- DRUG Amifostine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2002-10 |
| Est. Completion | 2007-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00318890
The ClinicalTrials.gov registry entry for NCT00318890 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Docetaxel is the first listed.
NCT00318890 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00318890 about?
NCT00318890 is a clinical study titled "Cisplatin and Docetaxel Plus Docetaxel and Radiotherapy With Amifostine for Squamous Cell Carcinoma of the Head and Neck". This trial seeks to accomplish both local and regional control of head and neck cancer and reduce systemic metastatic disease. To do this, patients will received chemotherapy followed by chemotherapy and radiation (given together) with an escalating dose of docetaxel.
What is the current status of trial NCT00318890?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2002-10. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00318890?
The interventions under investigation include: Docetaxel (DRUG), Cisplatin (DRUG), Radiotherapy (PROCEDURE), Amifostine (DRUG).
Who is sponsoring clinical trial NCT00318890?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.